Form 4: United Therapeutics CEO sells under 10b5-1 plan

CEO Martine Rothblatt exercised options at $120.26 and sold 8,000 shares on Nov. 14 and Nov. 17, 2025 under a pre-set Rule 10b5-1 plan.

Summary

• Martine A. Rothblatt (Chairperson & CEO) executed a pre-arranged Rule 10b5-1 plan entered on May 2, 2025 to exercise stock options at $120.26 and sell resulting shares.
• Transactions on 11/14/2025: exercised 4,000 options and sold 500 shares at $460.34, 2,000 at a weighted average $461.826, 930 at a weighted average $464.8428, and 570 at $466.05; direct holdings ended the day at 130 shares.
• Transactions on 11/17/2025: exercised 4,000 options and sold 1,500 shares at a weighted average $466.26 and 2,500 at a weighted average $468.3209; direct holdings ended the day at 130 shares.
• Total over the two days: 8,000 options exercised at $120.26 and 8,000 shares sold at approximately $460–$468 per share.
• Derivative position after exercises: 94,000 options (post 11/14/2025) and 90,000 options (post 11/17/2025) remain from a grant expiring 03/15/2026.
• Indirect beneficial ownership disclosed: 166 shares by spouse; 324,518 shares by family trusts (footnote 6); 258,117 shares by family trusts (footnote 7); 45,596 shares by family trusts (footnote 8); 15,962 shares by family trusts (footnote 9).
• The 10b5-1 plan will continue until the earlier of exhausting a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025.
• Weighted-average prices reflect multiple trades within stated ranges; full trade details available upon request per the footnotes.

Sentiment

Score: 5

Explanation: Routine, pre-planned insider selling under a Rule 10b5-1 plan; neutral from a fundamentals standpoint though ongoing sales may create modest supply overhang.

Positives

• Sales executed under a pre-arranged Rule 10b5-1 plan (adopted 05/02/2025), providing transparency and reducing information asymmetry.
• Option exercises were deeply in-the-money (exercise price $120.26 vs. sale prices around $460–$468), indicating substantial intrinsic value realization.
• Specific trade ranges and weighted-average prices disclosed, with a commitment to provide detailed trade breakdowns upon request.

Negatives

• CEO insider selling totaled 8,000 shares over two trading days, which some investors may view as a negative signal.
• Plan contemplates continued selling activity until the earlier of exhausting a tranche of 294,000 options (expiring 03/15/2026) or 12/31/2025, implying potential ongoing insider supply.
• Direct share ownership reported at 130 shares after each day’s sales (excluding indirect holdings), highlighting limited direct common stock retained.

Future Outlook

Under the Rule 10b5-1 plan adopted on May 2, 2025, periodic option exercises and corresponding sales may continue until the earlier of exhausting a tranche of 294,000 options expiring March 15, 2026 or December 31, 2025.

Management Comments

• Exercise and sale activity was conducted under a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025.
• The plan will continue until the earlier of exhausting a tranche of 294,000 stock options that expire on March 15, 2026 or December 31, 2025.
• Weighted-average prices are reported for transactions executed in multiple trades; full trade details will be provided upon request to SEC staff, the issuer, or a security holder.

Industry Context

Use of Rule 10b5-1 trading plans for scheduled option exercises and sales is common among large-cap biotech and pharma executives, particularly when options approach expiration, to diversify holdings and avoid blackout period constraints.

Comparison to Industry Standards

• Transaction structure aligns with peer practices at large-cap biopharma companies (e.g., Amgen, Gilead, Regeneron), where executives utilize 10b5-1 plans to systematically exercise and sell options ahead of expiration.
• The in-the-money multiple (sale prices roughly $460–$468 vs. $120.26 strike) is consistent with typical long-dated option programs that have appreciated substantially; realizing value via scheduled sales is standard risk management.
• Disclosure of weighted-average prices with ranges and an offer to provide detailed trade data upon request mirrors best-practice transparency standards for insider transactions.

Related Party Transactions

• Indirect beneficial ownership disclosed: 166 shares by spouse.
• Indirect beneficial ownership disclosed: 324,518 shares by family trusts (fn. 6).
• Indirect beneficial ownership disclosed: 258,117 shares by family trusts (fn. 7).
• Indirect beneficial ownership disclosed: 45,596 shares by family trusts (fn. 8).
• Indirect beneficial ownership disclosed: 15,962 shares by family trusts (fn. 9).

Stakeholder Impact

• Predictable insider selling through year-end under a disclosed 10b5-1 plan may modestly influence short-term sentiment and trading dynamics.
• No dilution or changes to corporate control implied; transactions reflect secondary market sales following option exercises.

Next Steps

• Continue executing the 10b5-1 plan until the earlier of exhausting the 294,000-option tranche or December 31, 2025.
• Provide detailed trade information upon request to SEC staff, the issuer, or a security holder, per footnotes.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, insider transaction, Rule 10b5-1, stock option exercise, insider selling, Martine Rothblatt, beneficial ownership, biotech